Novo Nordisk's Wegovy earns B+ from US nonprofit research organization

The Institute for Clinical and Economic Review has reviewed the Danish firm’s obesity drug next to other treatments, concluding it is better overall but more expensive than typical cost-effectiveness thresholds.

Photo: Novo Nordisk / PR

Novo Nordisk’s Wegovy is a ”step forward” when it comes to increasing the weight loss of people with obesity, according to US-based nonprofit research organization the Institute for Clinical and Economic Review, or ICER, which has assessed the comparative clinical effectiveness of several obesity treatments.

”There was also recognition that the addition of medications, such as the GLP-1 receptor agonists, represents a step forward in the magnitude of weight loss achieved, but they do not work for everyone, and the weight loss achieved is still less than that seen for bariatric surgery for many individuals,” ICER’s recently published report reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs